The genetic engineering industry in the US is dynamic and transformative, focusing on altering organisms’ DNA to develop new therapies, crops, and materials. Companies in this field include biopharmaceutical firms creating gene therapies, agricultural businesses using genetically modified organisms to enhance yields, and tech firms innovating genome-editing tools. With advancements like CRISPR and increased investment in healthcare technologies, the industry is rapidly evolving. Experts predict substantial growth in applications ranging from precision medicine to sustainable agriculture, as genetic engineering continues to push boundaries, offering solutions to some of society's most pressing challenges, like disease and food security.

This article showcases 14 prominent investors driving innovation in the genetic engineering sector. With a mix of venture capital firms, corporate giants, and private equity players, these investors are based in major cities like New York, Chicago, and San Francisco. Since their founding from 1946 to 2017, they have collectively engaged in over 336 investment deals in 2024. With operations typically involving teams of 11-5000 people, these investors exemplify a strong commitment to funding groundbreaking work in biotechnology and gene editing, cultivating a portfolio that reflects the industry's exciting potential.

Top 14 Genetic Engineering Investors in the US

1. OrbiMed

• Website: orbimed.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1989
• Headcount: 51-200
• Number of deals in 2024: 52
• LinkedIn: orbimed-advisors

OrbiMed is an investment firm specializing in healthcare investments, founded in 1989 and based in New York, New York. With approximately $17 billion in assets under management, OrbiMed focuses on biopharmaceuticals, medical devices, and healthcare services. The firm has made notable investments in the genetic engineering space, including a $70 million Series B financing for Intellia Therapeutics, which is developing gene editing technologies. Additionally, OrbiMed invested in Scribe Therapeutics, which raised $100 million to support gene editing and delivery technologies. Furthermore, OrbiMed participated in the $81 million Series B round for Evozyne, a company utilizing AI for drug discovery, and has shown interest in EmendoBio, which is pioneering a next-generation gene editing platform. These transactions highlight OrbiMed's active role in fostering innovation within the genetic engineering field.

2. Y Combinator

• Website: ycombinator.com
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2005
• Headcount: 51-200
• Number of deals in 2024: 802
• LinkedIn: y-combinator

Y Combinator is a prominent startup accelerator and venture capital firm based in San Francisco, California, founded in 2005. It provides funding and mentorship to early-stage technology companies through a structured program that helps entrepreneurs launch and grow their businesses. Y Combinator has successfully launched over 4,000 startups, making it a key player in the technology startup ecosystem. Among its diverse portfolio, Y Combinator has invested in several companies relevant to genetic engineering, including Algen Biotechnologies, which raised $5.4 million in a seed round in 2022, and 64x Bio, which also received seed funding. These investments highlight Y Combinator's engagement with innovative companies in the biotechnology and genetic engineering sectors, further solidifying its role as a significant investor in this field.

3. Sosv

• Website: sosv.com
• Type: Venture Capital
• Headquarters: United States (USA)
• Founded year: 1995
• Headcount: 51-200
• Number of deals in 2024: 170
• LinkedIn: sosv

Sosv is a venture capital firm founded in 1995, based in the United States, specializing in funding and supporting deep tech startups through its development programs. With a focus on health and climate technology, Sosv connects innovative companies with investors globally. Notably, they have invested in DNALite Therapeutics, a company dedicated to advancing genetic engineering solutions. Sosv's transactions with DNALite include multiple funding rounds, such as a convertible note in 2021 and a significant Series A round in 2022, where DNALite raised nearly $9 million to accelerate product development. Additionally, Sosv has also invested in Indee Labs, which further emphasizes their engagement in the genetic engineering sector. Overall, Sosv's investment strategy aligns well with the genetic engineering industry, showcasing their commitment to fostering innovation in this area.

4. ARCH Venture Partners

• Website: archventure.com
• Type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Founded year: 1986
• Headcount: 11-50
• Number of deals in 2024: 32
• LinkedIn: arch-venture-partners

ARCH Venture Partners is a venture capital firm founded in 1986, based in Chicago, Illinois, specializing in biotechnology investments. They provide funding and strategic support to early-stage biotech companies, helping them navigate the complexities of bringing new technologies to market. Notably, ARCH has been involved in significant transactions within the genetic engineering space, including a Series B financing round for Beam Therapeutics, which raised $135 million to expand its CRISPR technology and pipeline. Additionally, they participated in the Series B round for Arbor Biotechnologies, which raised $215 million to advance gene-editing technology platforms. Their portfolio includes companies that are at the forefront of genetic engineering, making them a key player in this industry.

5. Perceptive Advisors

• Website: perceptivelife.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1999
• Headcount: 11-50
• Number of deals in 2024: 45
• LinkedIn: perceptive-advisors-llc

Perceptive Advisors is a New York-based venture capital firm founded in 1999, specializing in the life sciences sector. The firm provides capital solutions and investment management services to both private and public healthcare companies, with a strong focus on biotechnology, pharmaceuticals, and medical devices. Their expertise in the healthcare industry enables them to support innovation and growth. Notably, Perceptive Advisors has been involved in significant transactions within the genetic engineering context, including investments in Beam Therapeutics, which focuses on gene editing technologies, and Precision BioSciences, known for its work in genome editing. Additionally, they invested in Synthego, a company that develops tools for gene editing, and Scribe Therapeutics, which is advancing gene editing and delivery technologies for treating neurodegenerative diseases. These investments highlight Perceptive Advisors' commitment to supporting advancements in genetic engineering.

6. Casdin Capital, LLC

• Website: casdincapital.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 2012
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn: casdin-capital-llc

Casdin Capital, LLC is a New York-based venture capital firm founded in 2012, specializing in the life sciences sector. The firm focuses on investing in healthcare, biotechnology, synthetic biology, and technology, providing funding and strategic partnerships to innovative companies. Notably, Casdin Capital has been involved in several significant transactions within the genetic engineering space, including a Series B investment in Editas Medicine, a leader in CRISPR technology, which raised $120 million in 2015. They also participated in Beam Therapeutics' post-IPO equity round, raising $260 million in 2021, and in Prime Medicine's $200 million Series B funding in 2021. Additionally, they were part of the financing rounds for Generation Bio, which is advancing gene therapy programs. These investments highlight Casdin Capital's commitment to supporting advancements in genetic engineering and biotechnology.

7. GV (Google Ventures)

• Website: gv.com
• Type: Venture Capital
• Headquarters: San Francisco Bay Area, California, United States (USA)
• Founded year: 2009
• Headcount: 51-200
• Number of deals in 2024: 74
• LinkedIn: gv

GV (Google Ventures) is a venture capital firm founded in 2009, based in the San Francisco Bay Area, California. With over $10 billion in assets under management, GV focuses on various sectors, including life sciences and artificial intelligence. The firm partners with innovative technology startups, providing funding and support to help them navigate the challenges of building successful companies. Notably, GV has invested in several key players in the genetic engineering space, such as Editas Medicine, a leader in CRISPR technology, and Beam Therapeutics, which focuses on precision genetic medicines. Additionally, GV has participated in funding rounds for Prime Medicine and Sana Biotechnology, both of which are advancing genetic engineering and therapeutic candidates. These investments highlight GV's active role in the genetic engineering industry, making them a significant player in this field.

8. IndieBio

• Website: indiebio.co
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 76
• LinkedIn: indiebio

IndieBio is a venture capital firm founded in 2015 and based in San Francisco, California. It specializes in biotechnology and provides investment, mentorship, and networking opportunities to startups in the biotech sector. IndieBio has been actively involved in funding innovative solutions across various sectors, including climate and food. Notably, they have invested in DNALite Therapeutics, a company focused on genetic engineering technologies, through multiple funding rounds, including a significant Series A round and several convertible notes. Their involvement with Indee Labs also highlights their commitment to supporting biotech entrepreneurs in advancing genetic engineering solutions. With a total of 76 investments in 2024 alone, IndieBio is a prominent player in the biotechnology investment landscape.

9. Pfizer

• Website: pfizer.com
• Type: Corporate
• Headquarters: New York, New York, United States (USA)
• Founded year: 1849
• Headcount: 10001+
• Number of deals in 2024: 10
• LinkedIn: pfizer

Pfizer Inc. is a leading pharmaceutical and biotechnology company founded in 1849, headquartered in New York, New York, USA. With over 10,000 employees, Pfizer develops and produces a wide range of medicines and vaccines aimed at improving patient health outcomes globally. In recent years, Pfizer has actively invested in the genetic engineering sector, participating in significant funding rounds for companies such as Caribou Biosciences, which raised $25 million in post-IPO equity, and Anjarium Biosciences, which secured CHF 55.5 million in a Series A financing round. Additionally, Pfizer Ventures has been involved in funding rounds for 4D Molecular Therapeutics, which focuses on advancing AAV gene therapies, showcasing Pfizer's commitment to supporting innovative genetic engineering solutions. These investments reflect Pfizer's strategic interest in harnessing genetic engineering to enhance therapeutic options and address urgent health needs.

10. Invus

• Website: invus.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1985
• Headcount: 51-200
• Number of deals in 2024: 35
• LinkedIn: invus

Invus is a New York-based venture capital firm founded in 1985, specializing in equity investments and investment management. The firm partners with owner-managers across various industries to enhance business performance and create sustainable value. Invus has a global reach and leverages its expertise to navigate complex investment landscapes. Notably, Invus has been involved in several key transactions in the genetic engineering sector, including a $115 million Series C financing for Caribou Biosciences, which focuses on CRISPR technology and immune cell therapies for oncology. Additionally, Invus participated in Generation Bio's funding rounds, contributing to their efforts in advancing gene therapies. Their investment in Korro Bio, which is also engaged in genetic engineering, further underscores their active role in this industry.

11. Redmile Group

• Website: redmilegroup.com
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2007
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn: redmile-group

Redmile Group is an investment management firm based in San Francisco, California, founded in 2007. The firm specializes in providing asset management and investment strategies to high-net-worth individuals and institutional investors. With a focus on the financial services sector, Redmile Group has made notable investments in the biotechnology and genetic engineering industries. Among its significant transactions, Redmile Group invested in Beam Therapeutics, which raised $260 million in post-IPO equity and is known for its work in CRISPR technology. Additionally, the firm participated in a $135 million Series B financing round for Beam Therapeutics, further supporting its development efforts. Redmile Group also invested in Silence Therapeutics, which raised approximately $120 million in a private placement aimed at advancing its clinical development in RNA therapies. Other investments include Prime Medicine and Mammoth Biosciences, both of which are engaged in innovative genetic engineering solutions. These transactions highlight Redmile Group's commitment to advancing genetic engineering and biotechnology.

12. Janus Henderson Investors

• Website: janushenderson.com
• Type: Private Equity
• Headquarters: Denver, Colorado, United States (USA)
• Founded year: 2017
• Headcount: 1001-5000
• Number of deals in 2024: 39
• LinkedIn: janus-henderson-emea

Janus Henderson Investors is a private equity firm based in Denver, Colorado, founded in 2017. The firm specializes in asset management, offering a diverse range of investment products including ETFs, mutual funds, and managed accounts. With a global operational footprint from its headquarters in London, Janus Henderson serves individual investors, financial professionals, and institutional clients, aiming to achieve superior financial outcomes through disciplined investment strategies. In recent years, Janus Henderson has made notable investments in the genetic engineering space, including a $40 million investment in Precision BioSciences in March 2024, which focuses on gene-editing technologies. They also co-led a $215 million Series B financing round for Arbor Biotechnologies in November 2021, which is advancing gene-editing technology for clinical applications. Additionally, they participated in a $115 million Series C financing for Caribou Biosciences in March 2021, a company known for its proprietary CRISPR technology platform. These transactions highlight Janus Henderson's active engagement in the genetic engineering industry.

13. New Enterprise Associates (NEA)

• Website: nea.com
• Type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Founded year: 1977
• Headcount: 51-200
• Number of deals in 2024: 57
• LinkedIn: new-enterprise-associates

New Enterprise Associates (NEA) is a prominent venture capital firm based in Menlo Park, California, founded in 1977. NEA specializes in investment management and advisory services for startups, particularly in the technology and healthcare sectors. The firm partners with entrepreneurs to provide funding and strategic guidance, helping them navigate the challenges of building successful businesses. NEA has made significant investments in the genetic engineering field, notably in CRISPR Therapeutics, where they participated in both Series A and Series B funding rounds in 2015, raising a total of $65 million. Additionally, NEA has invested in Korro Bio, a company focused on RNA-targeted therapies, participating in their Series A and Series B funding rounds, as well as a Post-IPO equity round in 2024. These transactions highlight NEA's active role in supporting innovative companies within the genetic engineering landscape.

14. Eli Lilly and Company

• Website: lilly.com
• Type: Corporate
• Headquarters: Indianapolis, Indiana, United States (USA)
• Founded year: 1876
• Headcount: 10001+
• Number of deals in 2024: 30
• LinkedIn: eli-lilly-and-company

Eli Lilly and Company is a pharmaceutical company based in Indianapolis, Indiana, founded in 1876. The company specializes in developing and delivering medicines for various health conditions, including diabetes and cancer. With over 10,000 employees and a robust investment strategy, Eli Lilly has made significant contributions to healthcare through innovative drug solutions and research initiatives. In recent years, they have actively invested in the genetic engineering sector, participating in notable transactions such as a $75 million investment in ProQR Therapeutics and a $60 million investment in Verve Therapeutics. Additionally, they contributed to a seed financing round for Amber Bio, a company focused on RNA editing platforms, showcasing their commitment to advancing genetic engineering technologies. These investments reflect Eli Lilly's strategic interest in harnessing genetic engineering to improve health outcomes.

Genetic Engineering Insights: Key Investors in the US

Investor	Headquarter	Size	Founded	Deals 2024
OrbiMed	New York, New York, United States (USA)	51-200	1989	52
Y Combinator	San Francisco, California, United States (USA)	51-200	2005	802
Sosv	United States (USA)	51-200	1995	170
ARCH Venture Partners	Chicago, Illinois, United States (USA)	11-50	1986	32
Perceptive Advisors	New York, New York, United States (USA)	11-50	1999	45
Casdin Capital, LLC	New York, New York, United States (USA)	11-50	2012	9
GV (Google Ventures)	San Francisco Bay Area, California, United States (USA)	51-200	2009	74
IndieBio	San Francisco, California, United States (USA)	1-10	2015	76
Pfizer	New York, New York, United States (USA)	10001+	1849	10
Invus	New York, New York, United States (USA)	51-200	1985	35
Redmile Group	San Francisco, California, United States (USA)	11-50	2007	15
Janus Henderson Investors	Denver, Colorado, United States (USA)	1001-5000	2017	39
New Enterprise Associates (NEA)	Menlo Park, California, United States (USA)	51-200	1977	57
Eli Lilly and Company	Indianapolis, Indiana, United States (USA)	10001+	1876	30

Want to find more investors focusing on the genetic engineering industry?

If you want to find more investors that are active in the genetic engineeringindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and their sizes.
• Portfolio: Companies they've invested in.
• Contact data: Key dealmakers, including their emails and phonenumbers.
• ...and much more!